Work

A Phase 1/2 trial of intratumoral (i.t.) IMO-2125 (IMO) in combination with checkpoint inhibitors (CPI) in PD-(L)1-refractory melanoma

Year: 2017

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdx376.052

Institutions: The University of Texas MD Anderson Cancer Center, Idera Pharmaceuticals (United States)

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2763799406

FWCI: 1.082

Cites:

Cited by: 13

Related to: 10